Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Chi-Med and Nestlé Form JV to Develop Chi-Med’s Lead Drug Candidate

publication date: Nov 28, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison Chi-Med and Nestlé announced the formation of a major new JV based on Chi-Med’s expertise in traditional Chinese medicines. The JV, which will be called Nutrition Science Partners Limited, will focus on innovative gastrointestinal TCM-based medicines and nutritional products. Although the description sounds like an OTC venture, it also includes Chi-Med’s lead drug candidate, HMPL-004, a TCM-derived drug. HMPL-004 will soon begin Phase III trials as a treatment for ulcerative colitis and Crohn’s disease. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners